Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 2—February 2020
Dispatch

Mycoplasma genitalium Antimicrobial Resistance in Community and Sexual Health Clinic Patients, Auckland, New Zealand

Anna Vesty, Gary McAuliffe, Sally Roberts, Gillian Henderson, and Indira BasuComments to Author 
Author affiliations: Auckland City Hospital, Auckland, New Zealand (A. Vesty, G. McAuliffe, S. Roberts, G. Henderson, I. Basu); Labtests, Auckland (G. McAuliffe)

Main Article

Table 2

Position and number of patients with mutations detected in the quinolone resistance–determining regions of the gyrA and parC genes in Mycoplasma genitalium strains from community and SHC patients, Auckland, New Zealand, 2017*

Gene and mutation† Amino acid change No. patients with mutation
Community patients SHC patients All patients References
gyrA
G285A Met → Ile (95) 1 4 5 (1,9)
G285T
 Met → Ile (95)
 0
 1
 1
 (11)
parC
C184T‡ Pro → Ser (61) 3 2 5 (1,9,11)
G241T Gly → Cys (81) 1 0 1 (1,12)
A247C Ser → Arg (83) 1 0 1 (1,3,9,12)
G248T Ser → Ile (83) 2 6 8 (1–3,9)
T249A Ser → Arg (83) 1 0 1
G259A Asp → Asn (87) 2 0 2 (1–3,8,9,11)
G259T Asp → Tyr (87) 2 3 5 (1,2,8,10)
C356T‡ Ala →Val (119) 1 0 1 (11)

*Nucleotide position and amino acid changes shown are based on M. genitalium numbering. SHC, sexual health clinic.
†Silent mutations not reported.
‡Fluoroquinolone resistance not determined.

Main Article

References
  1. Tagg  KA, Jeoffreys  NJ, Couldwell  DL, Donald  JA, Gilbert  GL. Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium. J Clin Microbiol. 2013;51:2245–9. DOIPubMedGoogle Scholar
  2. Couldwell  DL, Tagg  KA, Jeoffreys  NJ, Gilbert  GL. Failure of moxifloxacin treatment in Mycoplasma genitalium infections due to macrolide and fluoroquinolone resistance. Int J STD AIDS. 2013;24:822–8. DOIPubMedGoogle Scholar
  3. Anderson  T, Coughlan  E, Werno  A. Mycoplasma genitalium macrolide and fluoroquinolone resistance detection and clinical implications in a selected cohort in New Zealand. J Clin Microbiol. 2017;55:3242–8. DOIPubMedGoogle Scholar
  4. Yamaguchi  Y, Takei  M, Kishii  R, Yasuda  M, Deguchi  T. Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium. Antimicrob Agents Chemother. 2013;57:1772–6. DOIPubMedGoogle Scholar
  5. Basu  I, Roberts  SA, Bower  JE, Henderson  G, Reid  M. High macrolide resistance in Mycoplasma genitalium strains causing infection in Auckland, New Zealand. J Clin Microbiol. 2017;55:2280–2. DOIPubMedGoogle Scholar
  6. Kikuchi  M, Ito  S, Yasuda  M, Tsuchiya  T, Hatazaki  K, Takanashi  M, et al. Remarkable increase in fluoroquinolone-resistant Mycoplasma genitalium in Japan. J Antimicrob Chemother. 2014;69:2376–82. DOIPubMedGoogle Scholar
  7. Jensen  JS, Björnelius  E, Dohn  B, Lidbrink  P. Use of TaqMan 5′ nuclease real-time PCR for quantitative detection of Mycoplasma genitalium DNA in males with and without urethritis who were attendees at a sexually transmitted disease clinic. J Clin Microbiol. 2004;42:683–92. DOIPubMedGoogle Scholar
  8. Deguchi  T, Maeda  S, Tamaki  M, Yoshida  T, Ishiko  H, Ito  M, et al. Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment. J Antimicrob Chemother. 2001;48:742–4. DOIPubMedGoogle Scholar
  9. Murray  GL, Bradshaw  CS, Bissessor  M, Danielewski  J, Garland  SM, Jensen  JS, et al. Increasing macrolide and fluoroquinolone resistance in Mycoplasma genitalium. Emerg Infect Dis. 2017;23:809–12. DOIPubMedGoogle Scholar
  10. Shimada  Y, Deguchi  T, Nakane  K, Masue  T, Yasuda  M, Yokoi  S, et al. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in parC associated with fluoroquinolone resistance. Int J Antimicrob Agents. 2010;36:255–8. DOIPubMedGoogle Scholar
  11. Hamasuna  R, Le  PT, Kutsuna  S, Furubayashi  K, Matsumoto  M, Ohmagari  N, et al. Mutations in parC and gyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains. PLoS One. 2018;13:e0198355. DOIPubMedGoogle Scholar
  12. Dumke  R, Thürmer  A, Jacobs  E. Emergence of Mycoplasma genitalium strains showing mutations associated with macrolide and fluoroquinolone resistance in the region Dresden, Germany. Diagn Microbiol Infect Dis. 2016;86:221–3. DOIPubMedGoogle Scholar
  13. Golden  MR, Workowski  KA, Bolan  G. Developing a Public Health Response to Mycoplasma genitalium. J Infect Dis. 2017;216(suppl_2):S420–6.
  14. Read  TRH, Jensen  JS, Fairley  CK, Grant  M, Danielewski  JA, Su  J, et al. Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis. 2018;24:328–35. DOIPubMedGoogle Scholar
  15. Bébéar  CM, Grau  O, Charron  A, Renaudin  H, Gruson  D, Bébéar  C. Cloning and nucleotide sequence of the DNA gyrase (gyrA) gene from Mycoplasma hominis and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. Antimicrob Agents Chemother. 2000;44:2719–27. DOIPubMedGoogle Scholar

Main Article

Page created: January 20, 2020
Page updated: January 20, 2020
Page reviewed: January 20, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external